This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Power calculations were not reported, but the sample size was large. Of an initial group of 4,297 patients enrolled at the 20 participating centres, 758 cases were selected to reach a tight control of blood pressure (aim lower than 150/85 mm Hg): 400 patients (mean age: 56.3 +/-8.1 years; 51% men) were given captopril and 358 patients (mean age: 56 +/-8.2 years; 57% men) received atenolol.
Study design
This was a randomised clinical trial, which was conducted in 20 centres within the UK. Randomisation was conducted using sealed opaque envelopes and was stratified by the coordinating centre for those with or without previous treatment for hypertension. Patients were followed for nine years and final data were available for almost all patients. No blind assessment of the outcomes was reported.
Analysis of effectiveness
Primary analysis was based on intention to treat. The analysis used twenty-one endpoints: fatal myocardial infarction (MI), non-fatal MI, sudden death, heart failure, angina, fatal stroke, non-fatal stroke, death from peripheral vascular disease, amputation, death from renal failure, renal failure, retinal photocoagulation, vitreous haemorrhage, blindness in one eye, cataract extraction, death from hyperglycaemia, death from hypoglycaemia, fatal accident, death from cancer, death from any other specified cause, and death from unknown cause. Survival function estimates were calculated using the Kaplan-Meier method. The study groups were comparable at baseline with respect to demographics and blood pressure.
Effectiveness results
The effectiveness results were not presented in the economic paper and have been taken from the paper reporting on the parent clinical trial. In the captopril (c) and atenolol (a) groups:
fatal MIs were 35 (c) and 24 (a) (relative risk (RR) for captopril: 1.31; 99% confidence interval (CI): 0.66 -2.59; p=0.31); non-fatal MIs were 30 (c) and 21 (a) (RR: 1.30; 99% CI: 0.63 -2.71; p=0.35); sudden deaths were 8 (c) and 3 (a) (RR: 2.42; 99% CI: 0.42 -13.82; p=0.18); heart failures were 12 (c) and 9 (a) (RR: 1.21; 99% CI: 0.39 -3.78; p=0.66); episodes of angina were 20 (c) and 25 (a) (RR: 0.72; 99% CI: 0.33 -1.56; p=0.27); episodes of fatal stroke were 4 (c) and 5 (a) (RR: 0.72; 99% CI: 0.13 -4.04; p=0.62); non-fatal strokes were 17 (c) and 12 (a) (RR: 1.28; 99% CI: 0.49 -3.38; p=0.51); deaths from peripheral vascular disease were 1 (c) and 0 (a); amputations were 5 (c) and 3 (a) (RR: 1.48; 99% CI: 0.23 -9.71; p=0.59); deaths from renal failure were 0 (c) and 2 (a); cases of renal failure were 4 (c) and 4 (a) (RR: 0.91; 99% CI: 0.15 -5.64; p=0.59); episodes of retinal photocoagulation were 37 (c) and 24 (a) (RR: 1.40; 99% CI: 0.71 -2.74; p=0.20); vitreous haemorrhages were 2 (c) and 1 (a) (RR: 1.83; 99% CI: 0.08 -42.98; p=0.62); cases of blindness in one eye were 10 (c) and 8 (a) (RR: 1.12; 99% CI: 0.33 -3.79; p=0.82);
